Additionally, it has been discovered that C3a and C5a receptor antagonists can alleviate glomerular fibrosis in DKD patients by improving the endothelial-myofibroblast transition by inhibiting the Wnt/β-catenin signaling pathway (23). Here, C3 is linked to diabetic kidney disease.